Ekso Bionics Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Deferred Revenues and Cost of Revenues

Deferred Revenues and Cost of Revenues

3 Months Ended

Mar. 31, 2017

Deferred Revenue Disclosure [Abstract]

6. Deferred Revenues and Cost of Revenues

In connection with our medical device sales and engineering services, the Company often receives cash payments before the earnings process is complete. In these instances, the Company records the payments as customer deposits until a device is shipped to the customer, or as customer advances in the case of engineering services until the earnings process is achieved. In both cases, the cash received is recorded as a component of deferred revenue.

Deferred revenues and deferred cost of revenues consist of the following:

	March 31, 2017		December 31, 2016
Customer deposits and advances	$	74	$	47
Deferred rental income		93		60
Deferred extended maintenance and support		1,584		1,523
Total deferred revenues		1,751		1,630
Less current portion		(975)		(825)
Deferred revenues, non-current	$	776	$	805

Deferred medical device unit costs	$	46	$	-
Less current portion		(46)		-
Deferred cost of revenue, non-current	$	-	$	-

- Definition

The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References + Details